Marshall Wace, LLP Cerevel Therapeutics Holdings, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $25.2 Million - $27.7 Million	647,074 Added 52.94%	1,869,340 $76.4 Million
Q1 2024 May 15, 2024	BUY	$40.88 - $43.27 $37.2 Million - $39.3 Million	909,304 Added 290.55%	1,222,266 $51.7 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $6.34 Million - $13.3 Million	312,962 New	312,962 $13.3 Million
Q2 2021 Aug 13, 2021	SELL	$12.56 - $29.69 $296,378 - $700,594	-23,597 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.37 - $17.74 $546,444 - $783,664	-44,175 Reduced 65.18%	23,597 $324,000
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $665,521 - $1.24 Million	67,772 New	67,772 $1.12 Million

147

127M

1.91M

2.7M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.